CD3 kappa (Max Delbruck Centrum)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD3 kappa (Max Delbruck Centrum)
Drug Alias NameCD3 delta soluble splice variant (Max Delbruck/Ascenion)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunomodulatorsT lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsVaccinationImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMax Delbruck Centrum Fur Molekulare Medizin
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMax Delbruck Centrum Fur Molekulare MedizinAscenion
Active IndicationsN/A
Inactive IndicationsVaccinationImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A